CureDRPLA Global Patient Registry

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-03-01

Study Completion Date

2031-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of the CureDRPLA Global Patient Registry is to establish a longitudinal database of patient-reported data on individuals affected with Dentatorubral-pallidoluysian atrophy (DRPLA) from anywhere in the world.

The CureDRPLA Global Patient Registry will address patient needs by:

* Expanding patient engagement by documenting quality of life outcomes.
* Providing anonymized data to the DRPLA research community on patient experience with the disease and priorities for treatment.
* Connecting DRPLA patients with opportunities to participate in clinical research.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Personalized Antisense Oligonucleotide for A Single Participant With ATN1 Gene Mutation

NCT07084311

Dentatorubral-Pallidoluysian Atrophy

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study

NCT06016946

Friedreich Ataxia

RECRUITING

Riluzole in Patients With Spinocerebellar Ataxia Type 7

NCT03660917

SCA7

RECRUITING PHASE2/PHASE3

Coronary Artery Disease in Patients With Friedreich's Ataxia

NCT04649866

Friedreich Ataxia

COMPLETED NA

Effect of Riluzole as a Symptomatic Approach in Patients With Chronic Cerebellar Ataxia

NCT00202397

Hereditary Ataxia Multiple Sclerosis Cerebellar Ataxia

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The CureDRPLA Global Patient Registry aims to collect data from Dentatorubral-pallidoluysian atrophy (DRPLA) patients worldwide to identify a well-characterized cohort for participation in retrospective and prospective research. Participants will be required to read and sign an IRB-approved informed consent document prior to accessing questionnaires within the Registry. The Registry is solely for patients diagnosed with DRPLA.

After informed consent is given, and assent for those age 12 to the age of consent, participants will be asked to complete a series of questionnaires to include information on demographics, specifics of diagnosis, medical history, research, functional mobility, quality of life, and health economics. Participants will be asked to indicate if they are interested in being contacted by the Registry Coordinator for potential participation in future clinical trials and/or studies. Participants will have the option to withdraw from the Registry at any time, and upon withdrawal, they will no longer be contacted from the Registry for any reason. Data that they have entered will remain part of the Registry, but their identification will not be released for any reason. Active participants in the Registry will receive yearly email reminders to update their questionnaire data to reflect the current status of disease progression.

The Registry is available in English, French, Italian, Japanese, Korean, and Portuguese to encourage DRPLA patients worldwide to register. Participation is completed online, please visit our website for more information https://curedrpla.org/en/global-patient-registry/

The REDCap Cloud platform will serve as the Registry Data Coordinating Center and will manage data entered into a web based electronic data capture (EDC) system that is 21 CFR Part 11 validated, ISO 27001 certified, HIPPA, CDISC, and GDPR compliant.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

DRPLA

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Individuals with DRPLA

This registry is for people with a diagnosis of Dentatorubral-pallidoluysian atrophy (DRPLA)

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Individuals of all ages with a self-reported diagnosis of DRPLA.
* Understand and sign the informed consent form (IFC). Participants who lack the capacity to consent (e.g. cognitively impaired individuals) will require consent from the legal authorized representative, and the assent of the subject will be obtained to the extent compatible with their capacity. Participants at age 12 to age of consent will require assent along with the consent of their parent or legal guardian.